查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2047072

自動化攪拌設備市場－全球產業規模、佔有率、趨勢、機會、預測：按技術、最終用戶、地區和競爭對手分類，2021-2031年

Automated Compounding Device Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 192 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球自動化配藥設備（腫瘤學）市場預計將從 2025 年的 3.3826 億美元成長到 2031 年的 5.4187 億美元，複合年成長率達到 8.17%。

這些專用機器人系統旨在高精度地製備危險的化療藥物，從而最大限度地減少人與有毒物質的接觸。市場成長的主要驅動力是提高藥物安全性的迫切需求（透過減少配藥錯誤）以及全球癌症發生率的上升，後者導致對化療製劑的需求增加。根據美國衛生系統藥劑師協會2024年報告，62.8%的醫院採用了輔助製備無菌製劑的技術，凸顯了醫院越來越依賴自動化來確保危險藥物處理的準確性和合規性。

市場概覽
預測期 2027-2031
市場規模：2025年 3.3826億美元
市場規模：2031年 5.4187億美元
複合年成長率：2026-2031年 8.17%
成長最快的細分市場 容積式混合系統
最大的市場 北美洲

儘管這些先進系統具有明顯的安全優勢，但需要大量的資金投入，這成為市場擴張的一大障礙。高昂的初始實施和營運成本，以及持續的維護和員工培訓費用，都阻礙了小規模醫療機構採用這項技術。因此，預算限制仍是限制各級醫療機構廣泛採用此技術的主要因素。

市場促進因素

全球癌症發生率的上升以及由此導致的化療需求激增，是腫瘤領域採用自動化配藥系統的主要促進因素。隨著患者數量的增加，醫院藥房面臨製備無菌化療藥物的巨大壓力，而人工配藥已無法滿足如此大規模的需求。自動化配藥系統透過大幅提高處理能力，同時保持免疫力缺乏患者所需的嚴格無菌標準，有效應對了這一數量上的挑戰。日益加重的疾病負擔進一步凸顯了這一迫切性。美國癌症協會於2025年1月發布的《2025年癌症事實與數據》報告預測，當年美國將新增超過204.1萬例癌症病例，凸顯了一個關鍵趨勢：人工配藥方法將無法滿足不斷成長的臨床需求。

同時，隨著對職業安全和減少接觸的日益重視，醫療機構正朝著機器人系統發展。處理危險的抗癌藥物會對藥師的健康構成嚴重威脅，包括長期暴露可能導致的致突變性和致癌性風險。監管機構正在製定更嚴格的指導方針，強制要求隔離措施，而自動化往往是實現這些措施最有效的方式。美國國家職業安全與健康研究所 (NIOSH) 於 2024 年 12 月發布的報告《醫療機構危險藥物清單（2024 版）》確認，新增了 25 種藥物到危險藥物類別中，擴大了需要嚴格隔離措施的物質範圍。這種技術轉型也得到了更廣泛的產業趨勢的支持。發表在 2025 年 9 月《藥學時報》上的報導指出，全球近 50% 的醫療機構計劃在年底前將人工智慧驅動的自動化技術融入其工作流程。

市場挑戰

自動化配藥系統所需的巨額資本投入是限制市場擴張的主要因素，尤其對於小規模的醫療機構而言更是如此。實施該系統不僅涉及高昂的機器人系統購買成本，還包括設施維修、軟體整合以及專業人員培訓等相關費用。這些經濟負擔對於預算有限的區域醫院和地方醫療中心來說是一個障礙，阻礙了它們從人工配製化療過渡到自動化配藥。因此，市場仍然集中在大規模學術研究中心，限制了其更廣泛的商業性滲透。

這種經濟障礙在主要醫療區域的採用率指標中也顯而易見。根據歐洲醫院藥劑師協會2024年的報告，歐洲只有不到30%的醫院藥局全面或部分採用了自動化技術。這項數據表明，儘管腫瘤科對藥品配發安全的需求至關重要，但這些技術帶來的經濟負擔阻礙了其廣泛應用。因此，市場難以擴大低階市場的銷量，這直接阻礙了整個產業的成長。

市場趨勢

轉向以重量為基礎的檢驗技術代表著安全性的一次根本性變革，超越了傳統的目測體積檢測法。隨著越來越多的醫療機構認知到基於重量的檢驗是確保抗癌藥物成分濃度的準確方法，這一趨勢正在加速發展。稱重檢查能夠檢測出人工方法難以發現的偏差，從而顯著減少給藥錯誤。然而，由於操作上的複雜性，此方法的普及仍處於起步階段。根據報導於2024年12月《藥學實務新聞》（Pharmacy Practice News）上題為「IVWMS（靜脈注射藥物驗證系統）的普及速度是否足夠？」的文章，截至2023年，僅有7.7%的醫院藥房採用稱重方法來檢驗劑量、體積和給藥情況。

此外，個人化醫療和基於基因組的劑量確定技術的興起正在重塑市場格局，這要求患者最佳化化療的精確度更高。目前的治療方法依賴生物標記主導的療法，需要根據個別基因譜量身定做的精確劑量，而只有機器人系統才能持續提供這種精準度。這就要求配藥設備能夠處理複雜的批量，並以零浪費的方式加工高價值生物製藥。監管方面的進展也凸顯了這個趨勢。根據個人化醫療聯盟2025年5月發布的報告《FDA的個人化醫療：2024年發展的範圍和意義》，FDA在2024年核准了18種新的個人化藥物，佔新核准治療性分子實體的38%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球自動化配藥設備（腫瘤科）市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依技術（重力式混合系統、體積式混合系統）
    • 依最終用戶（醫院、化療中心等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美自動化配藥設備（腫瘤科）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲自動化配藥設備（腫瘤科）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區自動化配藥設備（腫瘤科）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲自動化配藥設備（腫瘤科）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲自動化配藥設備（腫瘤科）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球自動化配藥設備（腫瘤科）市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Baxter International Inc.
  • B. Braun SE.
  • COMECER SpA
  • ARxIUM Inc.
  • Omnicell Inc.
  • Grifols, SA
  • Weibond Technology
  • Equashield LLC.
  • ICU Medical, Inc
  • NewIcon Oy

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20041

The Global Automated Compounding Device (Oncology) Market is projected to expand from USD 338.26 Million in 2025 to USD 541.87 Million by 2031, achieving a compound annual growth rate of 8.17%. These specialized robotic systems are engineered to prepare hazardous chemotherapy medications with high precision, thereby minimizing human contact with toxic substances. The market's growth is primarily fueled by the critical necessity to improve medication safety by mitigating compounding errors and the rising global prevalence of cancer, which requires increased volumes of chemotherapy preparations. As reported by the American Society of Health-System Pharmacists in 2024, technologies assisting in sterile product preparation were employed in 62.8% of hospitals, highlighting the growing reliance on automation to ensure accuracy and compliance in handling hazardous drugs.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 338.26 Million
Market Size 2031USD 541.87 Million
CAGR 2026-20318.17%
Fastest Growing SegmentVolumetric Compounding System
Largest MarketNorth America

Despite the evident safety advantages, the market's expansion encounters a major obstacle due to the significant capital investment needed for these sophisticated systems. The high upfront costs of acquisition and implementation, along with the ongoing expenses for maintenance and staff training, frequently discourage smaller healthcare facilities from adopting this technology. Consequently, budgetary constraints persist as a primary barrier that prevents widespread deployment across all levels of healthcare providers.

Market Driver

The escalating global prevalence of cancer and the resulting surge in demand for chemotherapy act as the main catalysts for the adoption of automated compounding devices in oncology. As patient numbers rise, hospital pharmacies face increasing pressure to generate sterile chemotherapy preparations at a scale that manual processes cannot sustainably support. Automation resolves this volume challenge by drastically boosting throughput while upholding the strict sterility standards necessary for immunocompromised patients. This urgency is underscored by the growing disease burden; the American Cancer Society's 'Cancer Facts & Figures 2025' report from January 2025 projected that over 2,041,000 new cancer cases would be diagnosed in the United States that year, indicating a critical trajectory where manual compounding methods will fail to meet expanding clinical needs.

Concurrently, a stronger emphasis on occupational safety and exposure reduction is driving healthcare facilities to transition toward robotic systems. Handling hazardous antineoplastic drugs presents severe health risks to pharmacy staff, including potential mutagenic and carcinogenic effects from prolonged exposure. Regulatory bodies are reacting with stricter guidelines that require containment strategies, which are often best realized through automation. According to the National Institute for Occupational Safety and Health's December 2024 'List of Hazardous Drugs in Healthcare Settings, 2024', 25 new drugs were added to the hazardous category, reinforcing the broadening scope of substances requiring strict containment. This shift toward technology is further evidenced by wider industry trends; an article in Pharmacy Times from September 2025 titled 'Intelligent Pharmacy' noted that nearly 50% of global healthcare organizations intended to incorporate AI-driven automation into their workflows by the end of the year.

Market Challenge

The considerable capital investment necessary for automated compounding devices serves as a major restraint on market expansion, specifically for smaller healthcare institutions. Procurement entails not only the high purchase price of the robotic systems but also extensive costs related to facility modifications, software integration, and specialized personnel training. These financial demands create a barrier for community hospitals and rural centers operating on restricted budgets, preventing them from transitioning away from manual chemotherapy preparation. As a result, the market remains heavily concentrated within large academic research centers, limiting broader commercial penetration.

This economic obstacle is evident in adoption metrics across major healthcare regions. As stated by the European Association of Hospital Pharmacists in 2024, fewer than 30% of hospital pharmacies in Europe had fully or partially adopted automation technologies. This statistic demonstrates that, despite the critical need for safety in oncology compounding, the financial burden of these technologies stifles widespread implementation. Consequently, the market struggles to capture volume in lower-tier segments, directly hampering the overall growth of the industry.

Market Trends

The transition toward gravimetric verification technologies marks a fundamental evolution in safety, moving beyond visual volumetric methods. This trend is gaining traction as facilities recognize that weight-based verification provides a precise method to ensure the concentration of oncology ingredients. Scale-based checks detect deviations that manual methods miss, significantly mitigating dosing errors. However, adoption remains early due to operational complexity; according to the 'Is IVWMS Adoption Rate Fast Enough?' article in Pharmacy Practice News from December 2024, gravimetrics to verify dose, amount, and volume was utilized by only 7.7% of hospital pharmacies overall in 2023.

Additionally, the rise of personalized medicine and genomic-based dosing is reshaping the market by demanding higher precision for patient-specific chemotherapy. Treatments now rely on biomarker-driven therapies requiring exact dosages tailored to an individual's genetic profile, necessitating the accuracy that only robotic systems can consistently deliver. This forces compounding devices to adapt to complex batch sizes and handle high-value biologics with zero waste. This trajectory is highlighted by regulatory trends; according to the Personalized Medicine Coalition's May 2025 report, 'Personalized Medicine at FDA: The Scope & Significance of Progress in 2024,' the FDA approved 18 new personalized medicines in 2024, representing 38% of newly approved therapeutic molecular entities.

Key Market Players

  • Baxter International Inc.
  • B. Braun SE.
  • COMECER S.p.A.
  • ARxIUM Inc.
  • Omnicell Inc.
  • Grifols, S.A.
  • Weibond Technology
  • Equashield LLC.
  • ICU Medical, Inc
  • NewIcon Oy

Report Scope

In this report, the Global Automated Compounding Device (Oncology) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Automated Compounding Device (Oncology) Market, By Technology

  • Gravimetric Compounding System
  • Volumetric Compounding System

Automated Compounding Device (Oncology) Market, By End User

  • Hospitals
  • Chemotherapy Centers
  • Others

Automated Compounding Device (Oncology) Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Automated Compounding Device (Oncology) Market.

Available Customizations:

Global Automated Compounding Device (Oncology) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Automated Compounding Device (Oncology) Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Gravimetric Compounding System, Volumetric Compounding System)
    • 5.2.2. By End User (Hospitals, Chemotherapy Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Automated Compounding Device (Oncology) Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Automated Compounding Device (Oncology) Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Automated Compounding Device (Oncology) Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Automated Compounding Device (Oncology) Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By End User

7. Europe Automated Compounding Device (Oncology) Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Automated Compounding Device (Oncology) Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By End User
    • 7.3.2. France Automated Compounding Device (Oncology) Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Automated Compounding Device (Oncology) Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Automated Compounding Device (Oncology) Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Automated Compounding Device (Oncology) Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By End User

8. Asia Pacific Automated Compounding Device (Oncology) Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Automated Compounding Device (Oncology) Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By End User
    • 8.3.2. India Automated Compounding Device (Oncology) Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Automated Compounding Device (Oncology) Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Automated Compounding Device (Oncology) Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Automated Compounding Device (Oncology) Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By End User

9. Middle East & Africa Automated Compounding Device (Oncology) Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Automated Compounding Device (Oncology) Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Automated Compounding Device (Oncology) Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Automated Compounding Device (Oncology) Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By End User

10. South America Automated Compounding Device (Oncology) Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Automated Compounding Device (Oncology) Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Automated Compounding Device (Oncology) Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Automated Compounding Device (Oncology) Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Automated Compounding Device (Oncology) Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Baxter International Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. B. Braun SE.
  • 15.3. COMECER S.p.A.
  • 15.4. ARxIUM Inc.
  • 15.5. Omnicell Inc.
  • 15.6. Grifols, S.A.
  • 15.7. Weibond Technology
  • 15.8. Equashield LLC.
  • 15.9. ICU Medical, Inc
  • 15.10. NewIcon Oy

16. Strategic Recommendations

17. About Us & Disclaimer